
Sign up to save your podcasts
Or


Paul Hagerman discusses a Review which highlights the latest clinical and molecular understanding of the FMR1 mutation and FXTAS.
By The Lancet NeurologyPaul Hagerman discusses a Review which highlights the latest clinical and molecular understanding of the FMR1 mutation and FXTAS.

43,660 Listeners

294 Listeners

529 Listeners

52 Listeners

112,362 Listeners

88 Listeners

514 Listeners

182 Listeners

58 Listeners

79 Listeners

0 Listeners